Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Get Free Report) CFO Aaron Ondrey sold 7,489 shares of Rocket Pharmaceuticals stock in a transaction that occurred on Friday, April 4th. The stock was sold at an average price of $5.29, for a total transaction of $39,616.81. Following the sale, the chief financial officer now owns 129,650 shares in the company, valued at approximately $685,848.50. This represents a 5.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Rocket Pharmaceuticals Trading Down 7.7 %
RCKT opened at $4.79 on Wednesday. The company has a fifty day moving average price of $8.82 and a two-hundred day moving average price of $12.42. Rocket Pharmaceuticals, Inc. has a 1-year low of $4.60 and a 1-year high of $26.98. The company has a market cap of $510.76 million, a P/E ratio of -1.74 and a beta of 1.00. The company has a current ratio of 6.05, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06.
Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last issued its earnings results on Monday, March 3rd. The biotechnology company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($0.68) by $0.06. Analysts predict that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on RCKT. BMO Capital Markets began coverage on shares of Rocket Pharmaceuticals in a research note on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 price objective on the stock. Jefferies Financial Group started coverage on Rocket Pharmaceuticals in a research report on Wednesday, December 18th. They issued a "buy" rating and a $29.00 price target on the stock. Canaccord Genuity Group lowered their price objective on Rocket Pharmaceuticals from $39.00 to $36.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Needham & Company LLC reduced their target price on Rocket Pharmaceuticals from $52.00 to $42.00 and set a "buy" rating on the stock in a report on Friday, February 28th. Finally, Scotiabank boosted their price target on shares of Rocket Pharmaceuticals from $51.00 to $52.00 and gave the stock a "sector outperform" rating in a research report on Monday, March 3rd. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $43.00.
View Our Latest Research Report on Rocket Pharmaceuticals
Hedge Funds Weigh In On Rocket Pharmaceuticals
A number of institutional investors have recently modified their holdings of RCKT. Charles Schwab Investment Management Inc. grew its position in Rocket Pharmaceuticals by 3.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 569,814 shares of the biotechnology company's stock valued at $10,524,000 after purchasing an additional 20,322 shares during the period. The Manufacturers Life Insurance Company grew its holdings in shares of Rocket Pharmaceuticals by 9.1% during the third quarter. The Manufacturers Life Insurance Company now owns 152,293 shares of the biotechnology company's stock valued at $2,813,000 after buying an additional 12,680 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Rocket Pharmaceuticals by 9.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,767 shares of the biotechnology company's stock worth $347,000 after acquiring an additional 1,675 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Rocket Pharmaceuticals by 1.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 119,633 shares of the biotechnology company's stock worth $2,210,000 after acquiring an additional 1,561 shares during the last quarter. Finally, Verition Fund Management LLC bought a new position in Rocket Pharmaceuticals in the 3rd quarter valued at about $290,000. 98.39% of the stock is owned by institutional investors and hedge funds.
Rocket Pharmaceuticals Company Profile
(
Get Free Report)
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
